ISSN: 2155-9570
Amani Badawi
Mansoura University, Egypt
Scientific Tracks Abstracts: J Clin Exp Ophthalmol
Purpose: To determine the effect of a topical dorzolamide 2% on the macular thickness and function in patients with diabetic cystoid macular edema (CME). Setting: Mansoura Ophthalmic Center, Mansoura University, Mansoura, Egypt. Methods: The study was planned as a prospective, non-randomized, controlled and interventional study. A total of 84 diabetic patients (93 eyes) with secondary cystoid macular edema were included in the study. All eyes received topical dorzolamide 2% every 8 hours/day for one month. Changes in best-corrected visual acuity (BCVA), intraocular pressure (IOP), and optical coherence tomography measurements were evaluated at one week, one month and 3 months post-treatment. Results: Mean (logMAR) best-corrected visual acuity pre-treatment and one week, 1 month, and 3 months post-treatment was 1.08�±0.26, 1.02�±0.28, 0.66�±0.24 and 0.87�±0.26, respectively. The mean baseline central macular thickness was 535.27 �± 97.4 �¼m and reduced to 420.87�±115.24 �¼m (21.4% reduction) at one week and 357.43�±125.8 �¼m (33.2% reduction) at one month and then showed slight increase and reached 376.23�±134.5 �¼m (29.7% reduction) at the end of 3 months, but still statistically significantly less than the baseline value. Conclusions: Topical dorzolamide 2% significantly improved BCVA and reduced mean central macular thickness at 3 months. It could be effective, affordable and safe therapy in treating non-refractory diabetic cystoids macular edema.
Amani Badawi has completed her PhD in 2012 from Mansoura University, Egypt. She has worked as an Assistant Lecturer of Ophthalmology, Mansoura Ophthalmic Center in Egypt from 2006-2012 and as a Lecturer of Ophthalmology in Mansoura Ophthalmic Center in Egypt from 2012 to till date. She has published three papers and has been serving as a Reviewer in two different journals.
Email: amanibadawi37@yahoo.com